When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

A drug projected to have over $3B peak sales potential, Oxbryta was added to Pfizer's (PFE) portfolio following its $5B acquisition of Global Blood Therapeutics in 2022. "For large pharma ...

and pulling its sickle cell disease treatment Oxbryta due to deaths in clinical trials. Pfizer declined to comment for the story. Gabelli's Jonas said he would like Pfizer to tighten its focus on ...

Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as ...

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...

This growth guidance considers the reduction of sales associated with the previously announced global withdrawal of Oxbryta. Pfizer Expects 2024 adjusted EPS of $2.75-$2.95 compared to prior ...

Pfizer last month abruptly decided to pull the centerpiece of the deal, sickle cell disease therapy Oxbryta, off global markets after new clinical data raised increased numbers of painful vaso ...